Gene Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRXM research report →
About the company
Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials.
- CEO
- Christopher J. Reinhard
- IPO
- 2000
- Employees
- 3
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $6.49K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 12.69%
- ROIC
- 38.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-518,000 · -159.77%
- EPS
- $-0.02 · -139.97%
- Op Income
- $-1,262,000
- FCF YoY
- -728.54%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 19.29
- Avg Volume
- 0
Get TickerSpark's AI analysis on CRXM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 21 | Jemapete Christopher J | other | 0 |
| Mar 17, 21 | Jemapete Christopher J | buy | 200,000 |
| Mar 16, 21 | Jemapete Christopher J | buy | 300,000 |
| Feb 26, 21 | Jemapete Christopher J | other | 0 |
| Mar 23, 15 | HUTCHISON MURRAY H | other | 50,000 |
| Mar 23, 15 | Leitch Andrew M | other | 50,000 |
| Feb 28, 14 | HUTCHISON MURRAY H | other | 50,000 |
| Feb 28, 14 | Leitch Andrew M | other | 50,000 |
| Feb 28, 14 | MULROY DENNIS | other | 50,000 |
Our CRXM coverage
Recent articles, reports, and earnings notes.
No research on CRXM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRXM report →Similar companies
Peers in the same neighborhood.